Cargando…
Building clinically relevant outcomes across the Alzheimer's disease spectrum
Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roundtable (AARR) meetings, there remains no...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234696/ https://www.ncbi.nlm.nih.gov/pubmed/34195350 http://dx.doi.org/10.1002/trc2.12181 |
_version_ | 1783714143909445632 |
---|---|
author | Rentz, Dorene M. Wessels, Alette M. Annapragada, Ananth V. Berger, Anna‐Karin Edgar, Chris J. Gold, Michael Miller, David S. Randolph, Christopher Ryan, J. Michael Wunderlich, Glen Zoschg, Megan Canniere Trépel, Dominic Knopman, David S. Staffaroni, Adam M. Bain, Lisa J. Carrillo, Maria C. Weber, Christopher J. |
author_facet | Rentz, Dorene M. Wessels, Alette M. Annapragada, Ananth V. Berger, Anna‐Karin Edgar, Chris J. Gold, Michael Miller, David S. Randolph, Christopher Ryan, J. Michael Wunderlich, Glen Zoschg, Megan Canniere Trépel, Dominic Knopman, David S. Staffaroni, Adam M. Bain, Lisa J. Carrillo, Maria C. Weber, Christopher J. |
author_sort | Rentz, Dorene M. |
collection | PubMed |
description | Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roundtable (AARR) meetings, there remains no consensus as to what constitutes a “clinically meaningful outcome” in the eyes of patients, clinicians, care partners, policymakers, payers, and regulatory bodies. Furthermore, the field has not come to agreement as to what constitutes a clinically meaningful treatment effect at each stage of disease severity. The AARR meeting on November 19–20, 2019, reviewed current approaches to defining clinical meaningfulness from various perspectives including those of patients and care partners, clinicians, regulators, health economists, and public policymakers. Participants discussed approaches that may confer clinical relevance at each stage of the disease continuum and fostered discussion about what should guide us in the future. |
format | Online Article Text |
id | pubmed-8234696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82346962021-06-29 Building clinically relevant outcomes across the Alzheimer's disease spectrum Rentz, Dorene M. Wessels, Alette M. Annapragada, Ananth V. Berger, Anna‐Karin Edgar, Chris J. Gold, Michael Miller, David S. Randolph, Christopher Ryan, J. Michael Wunderlich, Glen Zoschg, Megan Canniere Trépel, Dominic Knopman, David S. Staffaroni, Adam M. Bain, Lisa J. Carrillo, Maria C. Weber, Christopher J. Alzheimers Dement (N Y) Perspective Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roundtable (AARR) meetings, there remains no consensus as to what constitutes a “clinically meaningful outcome” in the eyes of patients, clinicians, care partners, policymakers, payers, and regulatory bodies. Furthermore, the field has not come to agreement as to what constitutes a clinically meaningful treatment effect at each stage of disease severity. The AARR meeting on November 19–20, 2019, reviewed current approaches to defining clinical meaningfulness from various perspectives including those of patients and care partners, clinicians, regulators, health economists, and public policymakers. Participants discussed approaches that may confer clinical relevance at each stage of the disease continuum and fostered discussion about what should guide us in the future. John Wiley and Sons Inc. 2021-06-26 /pmc/articles/PMC8234696/ /pubmed/34195350 http://dx.doi.org/10.1002/trc2.12181 Text en © 2021 the Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Perspective Rentz, Dorene M. Wessels, Alette M. Annapragada, Ananth V. Berger, Anna‐Karin Edgar, Chris J. Gold, Michael Miller, David S. Randolph, Christopher Ryan, J. Michael Wunderlich, Glen Zoschg, Megan Canniere Trépel, Dominic Knopman, David S. Staffaroni, Adam M. Bain, Lisa J. Carrillo, Maria C. Weber, Christopher J. Building clinically relevant outcomes across the Alzheimer's disease spectrum |
title | Building clinically relevant outcomes across the Alzheimer's disease spectrum |
title_full | Building clinically relevant outcomes across the Alzheimer's disease spectrum |
title_fullStr | Building clinically relevant outcomes across the Alzheimer's disease spectrum |
title_full_unstemmed | Building clinically relevant outcomes across the Alzheimer's disease spectrum |
title_short | Building clinically relevant outcomes across the Alzheimer's disease spectrum |
title_sort | building clinically relevant outcomes across the alzheimer's disease spectrum |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234696/ https://www.ncbi.nlm.nih.gov/pubmed/34195350 http://dx.doi.org/10.1002/trc2.12181 |
work_keys_str_mv | AT rentzdorenem buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT wesselsalettem buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT annapragadaananthv buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT bergerannakarin buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT edgarchrisj buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT goldmichael buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT millerdavids buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT randolphchristopher buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT ryanjmichael buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT wunderlichglen buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT zoschgmegancanniere buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT trepeldominic buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT knopmandavids buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT staffaroniadamm buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT bainlisaj buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT carrillomariac buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum AT weberchristopherj buildingclinicallyrelevantoutcomesacrossthealzheimersdiseasespectrum |